Affiliation: Gilead Sciences
- Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256Hongmei Mo
Gilead Sciences Inc, Foster City, CA, USA Electronic address
Antiviral Res . 2017..The R155, A156 and D168 substitutions identified in patients confer reduced susceptibility to GS-9256 and other PIs in vitro...
- Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitorsH Mo
Department of Clinical Virology, Gilead Sciences Inc, Foster City, CA, USA
J Viral Hepat 18:338-48. 2011..This method provides a framework for the evaluation of other classes of drugs that are bound by serum proteins but require the presence of serum for in vitro evaluation...
- Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolatesS C C Sun
Department of Clinical Virology, Gilead Sciences, Inc, Foster City, CA 94404, USA
J Viral Hepat 18:861-70. 2011..In addition, the lack of correlation among the susceptibilities to three classes of HCV polymerase inhibitors evaluated here supports their possible combined use in a combination therapy strategy...
- Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190H Mo
Gilead Sciences Inc, Foster City, CA, USA
J Viral Hepat 23:644-51. 2016..Y448H confers reduced susceptibility to GS-9190 and other NNIs and persisted in most patients for months post-treatment. ..